The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells

Leukemia

Volumn 18, Issue 7, 2004, Pages 1207-1214

  Lucas, D M ^a   Davis, M E ^a   Parthun, M R ^a   Mone, A P ^a   Kitada, S ^b   Cunningham, K D ^a   Flax, E L ^a   Wickham, J ^a   Reed, J C ^b   Byrd, J C ^a,c   Grever, M R ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b BURNHAM INSTITUTE   (United States)

^c NONE   (United States)

Author keywords

Bcl 2; Chronic lymphocytic leukemia; Histone deacetylase

Indexed keywords

CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; FLICE INHIBITORY PROTEIN; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [N (PYRIDIN 3 YL METHOXYCARBONYL)AMINOMETHYL]BENZAMIDE; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; CARRIER PROTEIN; CFLAR PROTEIN, HUMAN; ENZYME INHIBITOR; HISTONE DEACETYLASE; N (2 AMINOPHENYL) 4 (N (PYRIDIN 3 YLMETHOXYCARBONYL)AMINOMETHYL)BENZAMIDE; N-(2-AMINOPHENYL)-4-(N-(PYRIDIN-3-YLMETHOXYCARBONYL)AMINOMETHYL)BENZAMIDE; PYRIDINE DERIVATIVE; SIGNAL PEPTIDE;

APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACETYLATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LC 50; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; MONONUCLEAR CELL; PRIORITY JOURNAL; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY; PHYSIOLOGY;

APOPTOSIS; BENZAMIDES; CARRIER PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASES; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, B-CELL, CHRONIC; LEUKOCYTES, MONONUCLEAR; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; REACTIVE OXYGEN SPECIES; TUMOR CELLS, CULTURED;

EID: 3142689788     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403388     Document Type: Article

References (31)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.
2. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001; 13: 477-483.
3. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1: 287-299.
4. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996; 93: 5705-5708.
5. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001; 61: 8492-8497.
6. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92: 1210-1216.
7. De Schepper S, Bruwiere H, Verhulst T, Steller U, Andries L, Wouters W et al. Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin. J Pharmacol Exp Ther 2003; 304: 881-888.
8. Coffey DC, Kutko MC, Glick RD, Swendeman SL, Butler L, Rifkind R et al. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol 2000; 35: 577-581.
9. Lee DY, Hayes JJ, Pruss D, Wolffe AP. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 1993; 72: 73-84.
10. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349-352.
11. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403: 41-45.
12. Wolffe AP, Guschin D. Review: chromatin structural features and targets that regulate transcription. J Struct Biol 2000; 129: 102-122.
13. Lee BI, Park SH, Kim JW, Sausville EA, Kim HT, Nakanishi O et al. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells. Cancer Res 2001; 61: 931-934.
14. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000; 97: 10832-10837.
15. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003; 63: 3637-3645.
16. Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002; 62: 6108-6115.
17. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
18. Weitkamp JH, Crowe Jr JE. Blood donor leukocyte reduction filters as a source of human B lymphocytes. Biotechniques 2001; 31: 464-466.
19. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151-157.
20. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW et al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 1999; 94: 1401-1408.
21. Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL et al. Flavopiridol induces apoposis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional b53. Blood 1998; 92: 3804-3816.
22. Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003; 102: 652-658.
23. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999; 96: 4592-4597.
24. Perkins C, Kim CN, Fang G, Bhalla KN. Arsenic induces apoptusis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 2000; 95: 1014-1022.
25. Amin HM, Saeed S, Alkan S. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of darxx in acute promyelocytic leukaemia with t(15;17). Br J Haematol 2001; 115: 287-297.
26. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. Role of caspases, Bid, and F53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 2003; 278: 12579-12589.
27. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001; 98: 10833-10838.
28. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055-4062.
29. Yi X, Yin XM, Dong Z. Inhibition of Bid-induced apoptosis by Bcl-2: tBid insertion, Bax translocation and Bax/Bak oligomerization suppressed. J Biol Chem 2003; 278: 25039-25045.
30. Kostelny SA, Link BK, Tso JY, Vasquez M, Jorgensen BH, Wang H et al. Humanization and characterization of the anti-HLA-DR antibody 1D10. Int J Cancer 2001; 93: 556-565.
31. Bellosillo B, Villamor N, Lopez-Guillermo A, Marce S, Bosch F, Campo E et al. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood 2002; 100: 1810-1816.